Koers IMV Inc. Toronto S.E.
Aandelen
IMV
CA44974L3011
Biotechnologie & Medisch Onderzoek
Omzet 2021 | - | Omzet 2022 | - | Marktkapitalisatie | 30,6 mln. 41,82 mln. 28,42 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -36 mln. -49,2 mln. -33,43 mln. | Nettowinst (verlies) 2022 | -38 mln. -51,93 mln. -35,29 mln. | EV/omzet 2021 | - |
Nettoliquiditeiten 2021 | 18,96 mln. 25,92 mln. 17,61 mln. | Nettoschuld 2022 | 7,67 mln. 10,49 mln. 7,13 mln. | EV/omzet 2022 | - |
K/w-verhouding 2021 |
-2,47
x | K/w-verhouding 2022 |
-0,53
x | Werknemers | 63 |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 99,93% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Andrew Hall
CEO | Chief Executive Officer | - | 10-11-20 |
Brittany Davison
DFI | Director of Finance/CFO | - | - |
Chief Operating Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 58 | 01-07-20 | |
Kyle Kuvalanka
BRD | Director/Board Member | 56 | 01-04-21 |
Markus Warmuth
BRD | Director/Board Member | 53 | 06-11-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+17,96% | 47,02 mld. | |
+48,77% | 41,86 mld. | |
+1,17% | 41,76 mld. | |
-4,27% | 28,8 mld. | |
+11,42% | 26,05 mld. | |
-21,39% | 19,15 mld. | |
+4,86% | 12,55 mld. | |
+27,29% | 12,34 mld. | |
-3,50% | 11,82 mld. |